Countable Labs announced it has raised $26 million in an oversubscribed financing round to accelerate clinical product development and global commercialization of its Countable PCR technology.
The financing round was led by ARCH Venture Partners with participation from F-Prime Capital and Primer Ventures. The company said the funding will support the development of fit-for-purpose solutions leveraging 10-color capabilities for applications including cell and gene therapy, minimal residual disease testing (MRD), biomarker validation, vaccine quality control, and molecular diagnostics.
Founded in 2019 and headquartered in Palo Alto, Countable Labs developed Countable PCR, a single-molecule quantification technology designed to provide higher sensitivity and precision than digital PCR while eliminating the need for Poisson correction and standard curves. The company said the platform is intended to support research, translational science, and industrial testing applications requiring rare event detection, molecular linkage analysis, and genome integrity assessment.
The funding will also support Countable Labs’ international commercial expansion under newly appointed Vice President of Global Sales Christopher Citraro. Citraro joins the company with nearly 20 years of life sciences sales experience, most recently serving in leadership roles at 10x Genomics. He previously held sales positions at Thermo Fisher Scientific, Agena Biosciences, and MP Biomedicals.
Countable Labs said Countable PCR delivers broad dynamic range, multiplexing capabilities, and the ability to detect rare genomic events with high confidence, positioning the technology for applications where digital PCR and next-generation sequencing are currently used.
KEY QUOTES:
“2026 is a critical year for Countable Labs’ momentum. This financing gives us the resources to ensure every laboratory that could benefit from a more sensitive genomics measurement solution finds Countable PCR. Our initial studies with clinical samples and use cases validated the technology’s robustness. Now we must develop and globally market new products for key customer segments, such as cell and gene therapy and MRD, where labs need easy-to-use precision measurement solutions that go beyond the capabilities of digital PCR.”
Giovanna Prout, Chief Executive Officer, Countable Labs
“PCR technology is widespread, but ready for disruption from faster, less expensive, and more robust technologies that remove the ambiguity that has plagued the industry. Countable Labs has completely reimagined PCR, creating a highly accurate, user-friendly solution ideal for distributed use across research, translational research, and industrial testing. These attributes position the company for long-term growth and success.”
Corey Ritter, Partner, ARCH Venture Partners
“Through our investment in Countable Labs, we aim to democratize access to new genomic tools, helping to bring rare event detection capabilities to customers around the world. From minimal residual disease testing to cell and gene therapy manufacturing to pathogen tracking, Countable PCR has the power and robustness to overtake many segments where digital PCR and next-generation sequencing currently dominate.”
Robert Weisskoff, Ph.D., Senior Partner, F-Prime Capital
“The future of genomic testing requires technologies that are simple, sensitive, and inexpensive, helping to democratize access to genomic diagnostics, and high-volume genome-based clinical and industrial testing. Countable PCR is exactly that, a technological step change that bridges the gap between complex digital PCR and the discoveries of next-generation sequencing, delivering clear, unambiguous results at scale.”
Christopher Citraro, Vice President Of Global Sales, Countable Labs
